Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches

doi:10.3390/pharmaceutics14091811

	Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches
	Ji, Qing 1; Wu, Yuchen 2; Albers, Andreas 3,4,5; Fang, Meiyu 1; Qian, Xu 2
刊名	PHARMACEUTICS
	2022-09-01
卷号	14
关键词	oncolytic viruses nanotechnology oncolytic virotherapy immunotherapy melanoma head and neck cancer
DOI	10.3390/pharmaceutics14091811
通讯作者	Fang, Meiyu(fangmy@zjcc.org.cn) ; Qian, Xu(qian_michelle2014@163.com)
英文摘要	Oncolytic virotherapy is a type of nanomedicine with a dual antitumor mechanism. Viruses are engineered to selectively infect and lyse cancer cells directly, leading to the release of soluble antigens which induce systemic antitumor immunity. Representative drug Talimogene laherparepvec has showed promising therapeutic effects in advanced melanoma, especially when combined with immune checkpoint inhibitors with moderate adverse effects. Diverse viruses like herpes simplex virus, adenovirus, vaccina virus, and so on could be engineered as vectors to express different transgenic payloads, vastly expanding the therapeutic potential of oncolytic virotherapy. A number of related clinical trials are under way which are mainly focusing on solid tumors. Studies about further optimizing the genome of oncolytic viruses or improving the delivering system are in the hotspot, indicating the future development of oncolytic virotherapy in the clinic. This review introduces the latest progress in clinical trials and pre-clinical studies as well as technology innovations directed at oncolytic viruses. The challenges and perspectives of oncolytic virotherapy towards clinical application are also discussed.
资助项目	National Key R&D Program of China[2019YFA0905800] ; Natural Science Foundation of Zhejiang Province[LGF21H200002] ; Internal Talent Program (Under Forty) of Zhejiang Cancer Hospital
WOS关键词	HERPES-SIMPLEX-VIRUS ; IMMUNOTHERAPEUTIC VACCINIA VIRUS ; CARRYING P53 GENE ; PEXA-VEC JX-594 ; PHASE-I TRIAL ; CAR-T CELL ; TALIMOGENE LAHERPAREPVEC ; INTRAVENOUS DELIVERY ; DOSE-ESCALATION ; SINGLE-ARM
WOS研究方向	Pharmacology & Pharmacy
语种	英语
出版者	MDPI
WOS记录号	WOS:000857534100001
资助机构	National Key R&D Program of China ; Natural Science Foundation of Zhejiang Province ; Internal Talent Program (Under Forty) of Zhejiang Cancer Hospital
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/128976]
专题	中国科学院合肥物质科学研究院
通讯作者	Fang, Meiyu; Qian, Xu
作者单位	1.Univ Chinese Acad Sci, Dept Rare & Head & Neck Oncol,Chinese Acad Sci, Key Lab Head & Neck Canc Translat Res Zhejiang Pr, Canc Hosp,Zhejiang Canc Hosp,Inst Basic Med & Can, Hangzhou 310022, Peoples R China 2.Univ Chinese Acad Sci, Dept Clin Lab, Zhejiang Canc Hosp, Canc Hosp,Inst Basic Med & Canc IBMC,Chinese Acad, Hangzhou 310022, Peoples R China 3.Charite Univ Med Berlin, Dept Otolaryngol Head & Neck Surg, Berlin Inst Hlth, D-13353 Berlin, Germany 4.Free Univ Berlin, D-13353 Berlin, Germany 5.Humboldt Univ, D-13353 Berlin, Germany
推荐引用方式 GB/T 7714	Ji, Qing,Wu, Yuchen,Albers, Andreas,et al. Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches[J]. PHARMACEUTICS,2022,14.
APA	Ji, Qing,Wu, Yuchen,Albers, Andreas,Fang, Meiyu,&Qian, Xu.(2022).Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches.PHARMACEUTICS,14.
MLA	Ji, Qing,et al."Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches".PHARMACEUTICS 14(2022).